In vivo experiments have also revealed that GSK343 (enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitor) could relieve peritoneal fibrosis, lipid deposition, and EMT by mitigating EZH2 and restoring klotho expression (Wang et al., 2023). The gene discussed is EZH2; the disease is Peritoneal Fibrosis.